Literature DB >> 29496649

Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.

Junru Chen1, Haoran Zhang1, Guangxi Sun1, Xingming Zhang1, Jinge Zhao1, Jiandong Liu1, Pengfei Shen1, Ming Shi2, Hao Zeng3.   

Abstract

OBJECTIVE: The aim of the study was to systematically review the relevant studies to evaluate the prognosis of primary and progressive muscle-invasive bladder cancer (MIBC) after radical cystectomy (RC) and provide a clue for the timing of RC in patients with progressive MIBC early at the time of high-risk non-muscle-invasive bladder cancer (NMIBC).
MATERIAL AND METHODS: PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched for eligible studies. We extracted hazard ratios (HRs) of overall survival (OS) and cancer-specific survival (CSS) and deaths at 5 and 10 years for each study and performed the meta-analysis using Review Manager 5.3.
RESULTS: A total of 11 retrospective studies with 4102 patients were included in the meta-analysis. The pooled analysis suggested a similar CSS (HR: 1.18; 95% CI, 0.74, 1.87; p = 0.50) and OS (HR: 1.15; 95% CI, 0.82, 1.61; p = 0.43) between primary and progressive MIBC patients treated with RC. The results further indicated no significant differences between the two populations in terms of 5-year CSS rate (OR: 1.32; 95% CI, 0.90, 1.95; p = 0.16), 10-year CSS rate (OR: 0.83; 95% CI, 0.37, 1.83; p = 0.64) as well as 5-year OS rate (OR: 1.02; 95% CI, 0.66, 1.56; p = 0.94). Subgroup analysis according to the starting point of follow-up showed similar outcomes.
CONCLUSION: The meta-analysis demonstrates comparable CSS and OS in patients with primary and progressive MIBC following RC. Novel risk stratifications and prospective trials are urgently needed to investigate the prognosis after RC of these two groups of patients, which could finally aid clinician decision making and select patients who would actually benefit from early RC.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Meta-analysis; Primary muscle-invasive bladder cancer; Prognosis; Progressive muscle-invasive bladder cancer; Radical cystectomy; Systematic review

Mesh:

Year:  2018        PMID: 29496649     DOI: 10.1016/j.ijsu.2018.02.049

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  4 in total

1.  Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients.

Authors:  Radosław Piliszek; Anna A Brożyna; Witold R Rudnicki
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

2.  Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.

Authors:  Nico C Grossmann; Pawel Rajwa; Fahad Quhal; Frederik König; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Satoshi Katayama; Reza Sari Motlagh; Christian D Fankhauser; Agostino Mattei; Marco Moschini; Piotr Chlosta; Bas W G van Rhijn; Jeremy Y C Teoh; Eva Compérat; Marek Babjuk; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat; Benjamin Pradere
Journal:  Eur Urol Open Sci       Date:  2022-04-01

3.  Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication.

Authors:  Raquel Carrasco; Laura Izquierdo; Antoine G van der Heijden; Juan José Lozano; Marco Franco; Mercedes Ingelmo-Torres; Fiorella L Roldan; Montserrat Llorens; María José Ribal; Lourdes Mengual; Antonio Alcaraz
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

Review 4.  Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.

Authors:  Mario Pones; David D'Andrea; Keiichiro Mori; Mohammad Abufraj; Marco Moschini; Eva Comperat; Shahrokh F Shariat
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.